| |
GAVI Board Teleconference
26 November 2001
Topics:
1. Recommendations from
the 5th Round of Country Proposal Review
- The Board again congratulated the Independent
Review Committee on its comprehensive and thorough review of the
country proposals received.
- The committee had reviewed proposals from
29 countries, comprising a total of 59 requests for immunization
services support, new vaccines and injection safety. In addition,
the committee had reviewed 14 inception reports from countries
that were approved for support in the first two rounds.
- The Board endorsed all of the recommendations
of the Independent Review Committee concerning new proposals.
Specific recommendations were that:
- requests for immunization services support
from Burundi, Cambodia, Comoros, Ethiopia, Gambia, Georgia,
Lesotho and Nepal receive approval;
- requests for vaccines from Benin, Burundi,
Georgia, Guinea, Mali, Nepal, Sri Lanka and Yemen receive
approval;
- requests for injection safety support
from Burundi, Cambodia, Ethiopia, Lao PDR, Nepal, and Sri
Lanka receive approval;
- requests for immunization services support
from Eritrea, Guinea, Lao PDR, Myanmar, Niger, Senegal, and
Sudan receive approval, with clarifications*;
- requests for vaccines from Gambia and
Moldova receive approval, with clarifications*;
- requests for injection safety support
from Georgia, Myanmar, Senegal, and Sudan receive approval,
with clarifications*;
- the proposal from India be handled separately,
with the recommendation be presented to the Board at a later
date
- The Board also endorsed the recommendation
of the IRC that all 14 inception reports received – from
Armenia, Azerbaijan, Cambodia, Ghana, Guyana, Kenya, Kyrgyz Repupblic,
Lao PDR, Liberia, Madagascar, Mali, Sâo Tomé &
Principe, Tanzania, Uganda – be considered satisfactory,
and that the second tranche of immunization services support be
released and vaccine orders be placed for those countries.
- The Board requests The Vaccine Fund Board
to approve the recommendations concerning new proposals, for which
financial implications are estimated to be $37,4 million for the
years 2002 and 2003. The five-year commitment is estimated to
be in the order of US$138 million, given current vaccine prices
and assuming that the countries consistently reach their targets
for immunized children.
- The Board also requests The Vaccine Fund
Board to approve the recommendation concerning the inception reports,
which represents a financial commitment estimated to be $34,3
million for the year 2002.
- The Chair proposed that at a future Board
meeting, the issue of why some Fund-eligible countries have not
yet submitted proposals should be reviewed.
* In line with current policy,
as soon as satisfactory clarifications are received at the Secretariat
these proposals will be considered approved.
2. Recommendations from
the IRC and the Working Group concerning cross-cutting issues
- Vaccine Supply: The
manufacturer of the combination vaccine DTP-hepB and DTP-hepB-Hib
is facing manufacturing difficulties and will not be able to meet
the projected needs of countries supported by GAVI and The Vaccine
Fund. The available supply of these vaccines will meet the needs
of countries that have already introduced these vaccines, but
there is not enough for newly approved countries.
- The Board supports the recommendation
that, in line with current GAVI policy, countries requesting
DTP-hepB be offered monovalent hepB, and countries requesting
DTP-hepB-Hib be offered monovalent hepB and combination DTP-Hib,
which will be available imminently. Also in line with current
policy, GAVI Partners are urged to provide extra support to
countries that are not able to receive their first-choice
vaccine presentations.
- The Board looks forward to the analyses being
commissioned by the Financing Task Force to examine the current
state of vaccine industry given recent major changes causing
significant capacity constraints, and to determine the lessons
learnt so far in the procurement of vaccines in line with
various partners’ responsibilities. These analyses will
be presented to the Board at its June 2002 meeting.
- The Netherlands encouraged GAVI partners
to support the Developing Country Vaccine Manufacturers network,
in light of the shortage in supply of combination vaccines.
- Communication with countries on supply
issues: The Board endorsed the recommendation
that UNICEF Supply Division prepare a notice concerning the vaccine
supply situatation, for distribution with decision letters to
countries. In addition, the Working Group members should distribute
this notice broadly to their regional and national constituencies,
specifically targetting the countries where the issue is most
pertinent.
- Additional Financial Support: The
Board requested that the Working Group consider new policies for
providing additional financial support to countries, and the longer-term
issues of financial sustainability, at its next meeting at the
end of November. The Working Group should indicate the financial
implications of, for example, providing a flat payment for all
countries introducing new vaccines, increasing the minimum amount
of funding for immunization services, prolonging the share investment,
or paying shares twice for each new child immunized. Recommendations
should be presented to the Board as soon as they are ready.
- Provision of AD Syringes to Eastern European
countries: The Board requested WHO to
follow up with WHO-Euro on CIS-CEE immunization schedules in order
to formulate a proposal for Board approval regarding whether the
Vaccine Fund should provide AD syringes based on national immunization
schedules or globally accepted minimum standards. Options should
be presented to the Board as soon as they are ready.
3. Finalization of Roles
and Responsibilities paper
Download Word
document (424kb)
- The paper is acceptable as it has been revised,
not as a final picture of the GAVI structures and relationships
but as a document that guides the upcoming work to determine the
future structures and mechanisms of the Alliance.
- The paper will be attached to the report
of this teleconference, rather than to the report of the Board
Meeting in Ottawa.
- A sub-group of the Board, led by the CDC,
will develop terms of reference for an external review of the
process and structures of GAVI and The Vaccine Fund, and the inter-relationship
between its functions. It is envisioned that this review would
be conducted in the first part of 2002, for presentation to the
Board at the June Board meeting.
4. Finalization of
Ottawa Meeting Summary Report
- Revised summary report is approved, with minor
adjustments.
Download
Report (Word document – 31kb)
5. Other Business
- The Board is requested to be available for
a teleconference the week of 10-15 January. The Secretariat will
follow up with further information on precise timing and agenda.
Return to GAVI Board
Documents
|
